Despite many recent advances in cancer treatments with breakthrough therapies, a large proportion of patients unfortunately develop resistance to their current treatment and are in need of new and better treatment options. Bolt is committed to addressing this unmet medical need.
Cancer can upregulate the expression of various immunosuppressive factors in the tumor microenvironment that inhibit the normal function of immune cells and limit their ability to create a productive anti-tumor immune response. Immuno-oncology approaches seek to harness the body’s own immune system to fight cancer. Our Boltbody ISACs act by seeking to reengage the immune system to generate a new anti-tumor immune response by activating the innate immune system which also leads to an adaptive immune response.
Human epidermal growth factor receptor 2, or HER2, is a gene that encodes a protein that promotes cell growth and differentiation. HER2 protein overexpression and gene amplification have been documented across multiple cancers. Therapeutics targeting of HER2 have had a major impact on patients with HER2-positive breast and gastric cancer, but there remains a huge amount of work to be done highlighted by a significant individual and global patient need.
Our lead product candidate, BDC-1001, is our HER2 Boltbody ISAC that seeks to improve therapeutic outcomes for patients with HER2-expressing tumors:
In addition, our innovative BDC-1001 approach seeks to address this critically important unmet medical need not only in patients with advanced tumors, but also in adjuvant settings.
BDC-1001 is currently in clinical development for the treatment of patients with HER2-expressing solid tumors, including subsets with HER2-low tumors. BDC-1001 is an ISAC; it is comprised of a HER2-targeting biosimilar trastuzumab which is conjugated to one of our proprietary TLR7/8 agonists, and is designed to maximize the potential anti-tumoral response of the immune system.
*By clicking “Learn More”, you will be navigated to a third-party website where you will be provided with additional information about Bolt Biotherapeutics’ clinical studies.